Development of small molecule inhibitors of IRAP - potential use for the treatment of memory disorders

Funded Activity Summary

This research project provides proof of concept that IRAP is a suitable target for use in the development of a new class of clinically valuable cognitive-enhancing agents. We have recently Identified a family of small molecule compounds that inhibited the catalytic activity of the enzyme using a molecule model of IRAP to screen virtual libraries. This research proposal aims to validate that this family of compounds have memory-enhancing properties by acting specifically on IRAP. At the conclusion of this project, we will have elucidated important information on the specificity of the memory effects and the structure activity relationship of this family of compounds. We will have identified and characterised a lead compound for development into a new class of cognitive enhancers.

Funded Activity Details

Start Date: 01-01-2007

End Date: 01-01-2007

Funding Scheme: NHMRC Development Grants

Funding Amount: $195,450.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Medical and Health Sciences not elsewhere classified

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

dementia | diabetes | diabetes mellitus | drug development | glucose homeostasis | learning and memory | memory-related disorders | metabolic disorders

Related Links